In December 2023, the British Pharmacological Society will present the Sir Henry Wellcome Gold Medal to Prof. V. Craig Jordan, CMG, OBE, DSc, PhD, FMedSci, FBPhS. This is the highest award for lifetime contributions to pharmacology by the British Pharmacological Society of Great Britain. Dr. Jordan is Professor of Breast Medical Oncology; Professor of Molecular and Cellular Oncology; and Chief, Section of Basic Science Research and Pharmacology, at The University of Texas MD Anderson Cancer Center, Houston. He has previously been recognized with the Society’s Gaddum Memorial Award for research contributions to pharmacology (1993), and the Sir James Black Award (2015) for contribution to drug discovery.
V. Craig Jordan, CMG, OBE, DSc, PhD, FMedSci, FBPhS
Prof. Jordan is a member of the National Academy of Sciences and the National Academy of Medicine; he is an honorary fellow of the Royal Society of Medicine. In 2008, he received the 38th David A Karnofsky Award, presented by ASCO. He was selected by ASCO as one of the 50 Oncology Luminaries in 2014 who changed the practice of oncology during the past 50 years.Prof. Jordan’s recent autobiographical journey “Tamoxifen Tales: Suggestions for Scientific Survival,” is published by Elsevier.
The Gold Medal was established in 1979 with a grant from Glaxo Wellcome (GlaxoSmithKline). The medal, featuring an image of Sir Henry Wellcome, was sculpted by Sir John Mills. GlaxoSmithKline continued its support until 2015, when the Council of the Society agreed to fund the award. The Wellcome name was retained to commemorate Sir Henry Wellcome, rather than his company. In 2023, to strengthen this association, the Society has renamed the award the ‘Sir Henry Wellcome Gold Medal.’
